Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF-alpha (infliximab) in early or progressing HAM/TSP
2007-005554-23Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab in HTLV-1-associated myelopathy (HAM), sponsored by Imperial College London. Primary endpoint: Clinical improvement versus baseline in early or progressing definite HTLV-1-associated myelopathy. Started Jan 2008; status: terminated.
02
Drugs
infliximab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on 2007-005554-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005554-23.